190 related articles for article (PubMed ID: 26740250)
1. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.
Stassijns J; Bollaerts K; Baay M; Verstraeten T
Vaccine; 2016 Feb; 34(6):714-22. PubMed ID: 26740250
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adults.
Baay M; Bollaerts K; Verstraeten T
Vaccine; 2018 Jul; 36(29):4207-4214. PubMed ID: 29885773
[TBL] [Abstract][Full Text] [Related]
3. Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Vaughn DW; Seifert H; Hepburn A; Dewe W; Li P; Drame M; Cohet C; Innis BL; Fries LF
Hum Vaccin Immunother; 2014; 10(10):2942-57. PubMed ID: 25483467
[TBL] [Abstract][Full Text] [Related]
4. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
[TBL] [Abstract][Full Text] [Related]
5. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
[TBL] [Abstract][Full Text] [Related]
6. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Cohet C; van der Most R; Bauchau V; Bekkat-Berkani R; Doherty TM; Schuind A; Tavares Da Silva F; Rappuoli R; Garçon N; Innis BL
Vaccine; 2019 May; 37(23):3006-3021. PubMed ID: 31031030
[TBL] [Abstract][Full Text] [Related]
7. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
8. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
[TBL] [Abstract][Full Text] [Related]
9. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
Fox CB; Haensler J
Expert Rev Vaccines; 2013 Jul; 12(7):747-58. PubMed ID: 23885820
[TBL] [Abstract][Full Text] [Related]
10. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
Patel SS; Bizjajeva S; Heijnen E; Oberye J
Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
[TBL] [Abstract][Full Text] [Related]
11. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Ahmed SS; Schur PH; MacDonald NE; Steinman L
J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
[TBL] [Abstract][Full Text] [Related]
12. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
13. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
Del Giudice G; Rappuoli R; Didierlaurent AM
Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
[TBL] [Abstract][Full Text] [Related]
14. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
[TBL] [Abstract][Full Text] [Related]
16. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
18. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
Schuind A; Segall N; Drame M; Innis BL
J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
